June Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
June Bai has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Changlei Bao
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China (D.L., C.B., H.T.).
1 shared publication - Chuangjia Huang
State Key Laboratory of Respiratory Disease;National Clinical Research Center for Respiratory Disease;National Center for Respiratory Medicine,;Guangzhou Institute of Respiratory Health;Department of Clinical Laboratory;The First Affiliated Hospital of Guangzhou Medical University, China
1 shared publication - Dan Bai
State Key Laboratory of Respiratory Disease;National Clinical Research Center for Respiratory Disease;National Center for Respiratory Medicine,;Guangzhou Institute of Respiratory Health;Department of Clinical Laboratory;The First Affiliated Hospital of Guangzhou Medical University;Shenzhen Key Laboratory of Microbial Genetic Engineering;Vascular Disease Research Center;College of Life Sciences and Oceanography, China
1 shared publication - Haiyang Tang
The First Affiliated Hospital of Guangzhou Medical University
1 shared publication - Hanliang Sun
State Key Laboratory of Respiratory Disease;National Clinical Research Center for Respiratory Disease;National Center for Respiratory Medicine;Guangzhou Institute of Respiratory Health;Department of Clinical Laboratory,;The First Affiliated Hospital of Guangzhou Medical University, China
1 shared publication - Jinsheng Zhu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China (C.H., J.B., L.Y., X.W., L.D., C.B., J.Z., J.L., J.F., Z.L., Y.X., H.S., S.L., H.T.).
1 shared publication
Latest Publications
- Open Access
- 12 February 2026
- Published by MDPI AG in Preprints.org
Mitochondrial-Endoplasmic Reticulum Axis (MERA) in Pulmonary Hypertension: A Critical Inter-Organellar Crossroads for Pathogenesis and Therapeutic Targets
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized primarily by sustained pulmonary vasoconstriction, pulmonary vascular remodeling, and elevated pulmonary artery pressure. Recent emerging studies have indicated that mitochondria-endoplasmic reticulum (ER) membrane (MAM) is increasingly implicated in pathogenesis of pulmonary hypertension (PH). Dysfunction of mitochondria or ER can trigger a series of pathological processes, including disrupted intracellular Ca2+ homeostasis, oxidative stress, ER stress, and inflammation, which in turn drive dysfunction of pulmonary artery smooth muscle (PASMCs) and endothelial cells (PAECs). This review article aims to systematically evaluates the pathogenic mechanisms of the MAM in PH, covering the latest research advances in mitochondrial dynamic disorders, Ca2+ homeostasis, ER stress, oxidative stress, cellular metabolic reprogramming, and inflammatory responses. Special focus is placed on the structural and functional regulatory mechanisms of MAMs and their roles in pulmonary vascular functional and structural dysfunction. Furthermore, the current review also discusses the potential of new and efficacious therapeutic strategies targeting mitochondrial dysfunctions and ER stress for treatments of PH.
- 12 February 2026
- Published by MDPI AG in Preprints.org
Open AccessMitochondrial-Endoplasmic Reticulum Axis (MERA) in Pulmonary Hypertension: A Critical Inter-Organellar Crossroads for Pathogenesis and Therapeutic Targets
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized primarily by sustained pulmonary vasoconstriction, pulmonary vascular remodeling, and elevated pulmonary artery pressure. Recent emerging studies have indicated that mitochondria-endoplasmic reticulum (ER) membrane (MAM) is increasingly implicated in pathogenesis of pulmonary hypertension (PH). Dysfunction of mitochondria or ER can trigger a series of pathological processes, including disrupted intracellular Ca2+ homeostasis, oxidative stress, ER stress, and inflammation, which in turn drive dysfunction of pulmonary artery smooth muscle (PASMCs) and endothelial cells (PAECs). This review article aims to systematically evaluates the pathogenic mechanisms of the MAM in PH, covering the latest research advances in mitochondrial dynamic disorders, Ca2+ homeostasis, ER stress, oxidative stress, cellular metabolic reprogramming, and inflammatory responses. Special focus is placed on the structural and functional regulatory mechanisms of MAMs and their roles in pulmonary vascular functional and structural dysfunction. Furthermore, the current review also discusses the potential of new and efficacious therapeutic strategies targeting mitochondrial dysfunctions and ER stress for treatments of PH.